Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
about
Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: a case report.Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II studySafety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathyReversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancerEffect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.Biological agents in gastrointestinal cancers: adverse effects and their management.Clinical relevance of KRAS in human cancers.Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study.Anti-VEGF Cancer Therapy in Nephrology PracticeThe relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review.Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.Napoleone Ferrara and the saga of vascular endothelial growth factor.Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugsCurrent intravitreal pharmacologic therapies for diabetic macular edema.The risk for anemia with targeted therapies for solid tumorsA phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.Roles for VEGF in the adult.VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependymaMechanisms of adverse effects of anti-VEGF therapy for cancer.Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertensionInhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitorAnti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational studyNeuropilins: novel targets for anti-angiogenesis therapies.Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.Antivascular endothelial growth factor antibody for treatment of glioblastoma multiformeVascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice.Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling.Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases.Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients.Safety profile of new anticancer drugs.Targeted therapies in the management of colorectal carcinoma: role of bevacizumab.Safety of bevacizumab in patients with metastatic breast cancer.Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.After counterfeit Avastin®--what have we learned and what can be done?Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature.Novel anti-angiogenic therapeutic strategies in colorectal cancer.Cardiotoxicity associated with targeted cancer therapies.Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis.
P2860
Q33380253-428174B8-4C87-4B72-970B-3DC9E3FC62E8Q33384793-B8E899B6-7BEB-43EF-B1C9-CB6DF4B7A808Q33392652-BD77A3D1-82E1-4D30-9F91-95125E2F35BAQ33411108-044A2597-7B57-43C6-8D59-037E5A7F3376Q33521675-2E37C25D-1BDE-4E29-BD40-A9F980731CD7Q33718385-267DFF37-A81B-411E-911F-60CDA95678A6Q33739583-99AE8651-AFFD-49D3-81D0-15AB4B8AD731Q33895581-DAAF1BFE-1520-45CE-BF44-55E14ECF150FQ33959887-07190BCB-D11A-4773-B791-E5042BCF3264Q33994024-460453AF-F653-4749-A194-6EBAAFE0D537Q34152125-26EE0A20-C667-4709-8259-1E69787BCF05Q34378757-4E9F17A5-D249-4D0F-A0F3-EC272ED2FB91Q34511156-31E0267C-A3F4-4B56-84BB-DF993735A800Q34787946-71396AA5-BAFE-4F75-B485-34001A340431Q35034404-080364B0-EC2A-4C50-AB62-F5D0B9711BA3Q35650268-B13973FE-4B2E-44B2-AF13-C3F916245BC5Q35989994-BC125B4E-4A0E-4714-B2C1-C303418D355CQ36105171-E46D9081-1310-43A3-8B7E-E45BEB9CC32DQ36248647-05708E2E-8AA2-41C3-A86A-9C591A585291Q36502881-74CCF75A-CCFE-4366-B6C0-2E70EE0C1832Q36609627-E0745DDE-444C-4360-BFD4-B02A553485F6Q36678295-D0F4AD64-76F8-4F77-97A3-0E89510E675AQ36734939-17264B5D-CEE8-4E8B-A52E-D7505E0ED9F0Q36858624-A90B0FF1-0BBF-4456-9A68-474F88884CFBQ37079862-30094056-D413-4EA0-AD2E-8667601A28FBQ37353319-B020DCB7-DC4C-480E-BBB4-4A2D79E6CAF7Q37372416-B4255043-6A70-4299-B05D-192E951CD1FEQ37400759-220DD699-9734-4A3F-B8D1-8E5A2AB795E4Q37416913-805B696D-C41B-4DFF-B7E7-10F355D6B139Q37432618-047731C3-8A78-4C04-8336-26C79A34A73EQ37633039-6A437D10-CC6D-4780-8694-94AB42AE232DQ37696502-CD74A7E6-2255-4D2E-BADA-96BF91D70DB2Q37771243-1BBBD3FB-1DB6-427A-9A35-630F10ECAA82Q37903602-32853125-3E77-49E6-A016-5970E9D3D63CQ38155097-093F06E1-6E18-4492-8313-F360A1BD9897Q38367161-E1DD8B5D-288D-4D1C-81B1-9256C73F7DBAQ38607235-5E62AB19-3309-46FA-A141-433CA37E9E78Q38759141-19DC9ADA-C790-46AA-9602-41D064533854Q38819670-3AA365EA-FADF-4C08-906B-3B67A1976E32Q38950984-8334CAA6-0BCF-4327-97E1-305579DE20A0
P2860
Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Bevacizumab in the treatment o ...... management of adverse events.
@ast
Bevacizumab in the treatment o ...... management of adverse events.
@en
type
label
Bevacizumab in the treatment o ...... management of adverse events.
@ast
Bevacizumab in the treatment o ...... management of adverse events.
@en
prefLabel
Bevacizumab in the treatment o ...... management of adverse events.
@ast
Bevacizumab in the treatment o ...... management of adverse events.
@en
P1433
P1476
Bevacizumab in the treatment o ...... management of adverse events.
@en
P2093
Herbert Hurwitz
Shermini Saini
P304
P356
10.1053/J.SEMINONCOL.2006.08.001
P433
5 Suppl 10
P577
2006-10-01T00:00:00Z